Only in Titles

           Search results for: Recombinant Human VEGF VEGFA [from CHO cells] Proteins    

paperclip

#30037214   // Save this To Up

Oleanolic Acids Inhibit Vascular Endothelial Growth Factor Receptor 2 Signaling in Endothelial Cells: Implication for Anti-Angiogenic Therapy.

Angiogenesis must be precisely controlled because uncontrolled angiogenesis is involved in aggravation of disease symptoms. Vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR-2) signaling is a key pathway leading to angiogenic responses in vascular endothelial cells (ECs). Therefore, targeting VEGF/VEGFR-2 signaling may be effective at modulating angiogenesis to alleviate various disease symptoms. Oleanolic acid was verified as a VEGFR-2 binding chemical from anticancer herbs with similar binding affinity as a reference drug in the Protein Data Bank (PDB) entry 3CJG of model A coordination. Oleanolic acid effectively inhibited VEGF-induced VEGFR-2 activation and angiogenesis in HU-VECs without cytotoxicity. We also verified that oleanolic acid inhibits angiogenesis during the development and the course of the retinopathy of prematurity (ROP) model in the mouse retina. Taken together, our results suggest a potential therapeutic benefit of oleanolic acid for inhibiting angiogenesis in proangiogenic diseases, including retinopathy.

1061 related Products with: Oleanolic Acids Inhibit Vascular Endothelial Growth Factor Receptor 2 Signaling in Endothelial Cells: Implication for Anti-Angiogenic Therapy.

Human Endocrine Gland Vas Rat Vascular Endothelial Mouse Vascular Endothelia Recombinant Human Vascula IGF-1R Signaling Phospho- Human Vascular Endothelia Mouse Vascular Endothelia Human Vascular Endothelia Mouse Vascular Endothelia GFP Expressing Human Inte Goat Anti-Human Endotheli Rat monoclonal anti mouse

Related Pathways

paperclip

#27231876   // Save this To Up

Prokaryotic Soluble Overexpression and Purification of Human VEGF165 by Fusion to a Maltose Binding Protein Tag.

Human vascular endothelial growth factor (VEGF) is a key regulator of angiogenesis and plays a central role in the process of tumor growth and metastatic dissemination. Escherichia coli is one of the most common expression systems used for the production of recombinant proteins; however, expression of human VEGF in E. coli has proven difficult because the E. coli-expressed VEGF tends to be misfolded and forms inclusion bodies, resulting in poor solubility. In this study, we successfully produced semi-preparative amounts of soluble bioactive human VEGF165 (hVEGF). We created seven N-terminal fusion tag constructs with hexahistidine (His6), thioredoxin (Trx), glutathione S-transferase (GST), maltose-binding protein (MBP), N-utilization substance protein A (NusA), human protein disulfide isomerase (PDI), and the b'a' domain of PDI (PDIb'a'), and tested each construct for soluble overexpression in E. coli. We found that at 18°C, 92.8% of the MBP-tagged hVEGF to be soluble and that this tag significantly increased the protein's solubility. We successfully purified 0.8 mg of pure hVEGF per 500 mL cell culture. The purified hVEGF is stable after tag cleavage, contains very low levels of endotoxin, and is 97.6% pure. Using an Flk1+ mesodermal precursor cell (MPC) differentiation assay, we show that the purified hVEGF is not only bioactive but has similar bioactivity to hVEGF produced in mammalian cells. Previous reports on producing hVEGF in E. coli have all been based on refolding of the protein from inclusion bodies. To our knowledge, this is the first report on successfully expressing and purifying soluble hVEGF in E. coli.

2400 related Products with: Prokaryotic Soluble Overexpression and Purification of Human VEGF165 by Fusion to a Maltose Binding Protein Tag.

Anti Galectin(Gal 3) Huma amyloid beta precursor pr Protein Purification Bea Recombinant Human Soluble Human Dnak (HSP70) His ta ribosome binding protein Protein Purification Bea Rabbit Anti-Human Toll In Recombinant Human Soluble Goat Anti-Human Vitamin D Mouse Anti-Human Retinol Rabbit Anti-Maltose Bindi

Related Pathways

  •  
  • No related Items
paperclip

#27130666   // Save this To Up

Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.

Both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF or FGF-2) are potent pro-angiogenic factors and play a critical role in cancer development and progression. Clinical anti-VEGF therapy trials had a major challenge due to upregulated expression of other pro-angiogenic factor, like FGF-2. This study developed a novel chimeric decoy receptor VF-Trap fusion protein to simultaneously block activity of both VEGF and FGF pathways in order to achieve an additive or synergistic anti-tumor effect. Our in vitro data showed that VF-Trap potently blocked proliferation and migration of both VEGF- and FGF-2-induced vascular endothelial cells. In animal models, treatment of xenograft tumors with VF-Trap resulted in significant inhibition of tumor growth compared to blockage of the single molecule, like VEGF or FGF blocker. In addition, VF-Trap was also more potent in inhibition of ocular angiogenesis in a mouse oxygen-induced retinopathy (OIR) model. These data demonstrated the potent anti-angiogenic effects of this novel VF-Trap fusion protein on blockage of VEGF and FGF-2 activity in vitro and in animal models. Further study will assess its effects in clinic as a therapeutic agent for angiogenesis-related disorders, such as cancer and ocular vascular diseases.

2766 related Products with: Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.

Rat Vascular Endothelial Mouse Vascular Endothelia Human Vascular Endothelia Human Vascular Endothelia Mouse Vascular Endothelia Mouse Vascular Endothelia Human Endocrine Gland Vas Goat Anti-Human Fibroblas Sheep Polyclonal Antibody Rabbit Polyclonal Antibod Recombinant Human Vascula Mouse Fibroblast Growth F

Related Pathways

paperclip

#   // Save this To Up


2452 related Products with:

No related Items

Related Pathways

  •  
  • No related Items
paperclip

#   // Save this To Up


2370 related Products with:

No related Items

Related Pathways

  •  
  • No related Items
paperclip

#   // Save this To Up


2466 related Products with:

No related Items

Related Pathways

  •  
  • No related Items
paperclip

#   // Save this To Up


1174 related Products with:

No related Items

Related Pathways

  •  
  • No related Items
paperclip

#   // Save this To Up


2174 related Products with:

No related Items

Related Pathways

  •  
  • No related Items
paperclip

#   // Save this To Up


2277 related Products with:

No related Items

Related Pathways

  •  
  • No related Items
paperclip

#   // Save this To Up


2274 related Products with:

No related Items

Related Pathways

  •  
  • No related Items